BioSpace News Archive

Celcuity Inc. announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Applied Therapeutics, Inc. announced that it will present full results from the Phase 3 ARISE-HF study evaluating AT-001 in Diabetic Cardiomyopathy in an oral presentation at the 2024 American College of Cardiology Annual Scientific Session to take place April 6-8, 2024 in Atlanta, Georgia.

Johnson & Johnson announced that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of Cardiology 73rd Annual Scientific Session & Expo taking place April 6-8, 2024, in Atlanta, Georgia.

Aethon Therapeutics, Inc. today announced that it has entered into a collaboration agreement with Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers.

Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces the launch of a new MyPhenomeTM test that now allows patients to test for all three identified phenotypes - Emotional Hunger, Hungry Gut and Hungry Brain - in one simple test.

ProfoundBio today announced its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5-10 in San Diego, California.

Zimmer Biomet Holdings, Inc. today announced partnerships with three top pickleball organizations in the United States, becoming the first and only medical device partner for the sport of pickleball.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2024, which ended February 29, 2024.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of its common stock to four new employees.

Sonoma Pharmaceuticals, Inc. reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for Microdox in the management of urinary tract infections.